The yearly MetaSystems Distributor Meeting (DM), brought into life in 2002 as a platform to gather all international partners of MetaSystems and other members of the global MetaSystems family, just ended last week. The DM is being organized in turns by MetaSystems Headquarters, MetaSystems USA (MGI), and MetaSystems Asia. Since MGI is celebrating its 25th anniversary in 2018 they decided to choose a special location: Nassau, The Bahamas!
XL t(6;9) DEK/NUP214
Translocation/Dual Fusion Probe
- Order Number
- Package Size
- 100 µl
Several recurrent balanced translocations and inversions, and their variants, are
recognized in the WHO category AML with recurrent genetic abnormalities. Three new
cytogenetically defined entities were recently incorporated: AML with t(6;9)(p23;q34) DEK/NUP214; AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) RPN1/EVI1 and AML (megakaryoblastic) with t(1;22)(p13;q13) RBM15/MKL1, a rare leukemia most commonly
occurring in infants.
The t(6;9)(p23;q34) DEK/NUP214 fusion occurs with an incidence of 1–5% in adult patients with AML. This translocation tends to occur in younger adults and is associated with an unfavorable prognosis at diagnosis. Although the t(6;9) is usually the sole cytogenetic aberration at diagnosis, additional karyotypic abnormalities are frequently identified during disease progression.
- Acute Myelogenous Leukemia (AML)
Two green (2G) and two orange (2O) signals.
Aberrant Cell (typical results):
One green (1G), one orange (1O), and two green-orange fusion signals (2GO).
- Shearer et al (2005) Leukemia 19: 126-131
- Doehner et al (2010) Blood 115: 453-474
- Sandahl et al (2014) Haematologica 99: 865-872